SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo Reports 21% of Frontline AML Patients Reached Transplant on Triplet

Aptevo said 10 of 47 evaluable newly diagnosed AML patients receiving mipletamig with venetoclax and azacitidine proceeded to allogeneic stem cell transplant, compared with 0.7% reported with VEN+AZA in VIALE-A. Dose optimization in RAINIER is expected to conclude by year-end 2026.

APVO

Related stories